Atropos Health, a company that turns real-world clinical data into personalized insights, has announced a new partnership with Novartis. This collaboration aims to develop, train, and test multiple AI models that help find people with rare diseases who haven’t been diagnosed yet. The goal is to shorten the time between when symptoms first show up and when patients get tested, diagnosed, and treated.
The partnership focuses on paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood condition. Many adults with PNH experience long delays in diagnosis, sometimes waiting over a year, and in some cases, more than five years. This is because PNH is rare and its symptoms can affect different organs in various ways. As part of the collaboration, Atropos Health has developed an AI model to detect potential PNH patients earlier. This can help healthcare systems speed up the process of proper diagnosis and treatment. The AI tool is now ready to be used within healthcare systems.
Health Technology Insights: Artera Agents Handle 42M Patient Sessions with 94% Success
Dr. Brigham Hyde, CEO and co-founder of Atropos Health, said, “Creating AI models that are tested and trained on high-quality real-world data is the next big step in precision medicine. The accuracy of these models reduces the guesswork, and getting testing earlier can be life-changing for patients. For healthcare providers and systems, faster diagnosis and treatment lead to better patient satisfaction.”
The aim of this collaboration is to create and share patient-finding models that shorten the time between symptom onset and diagnosis and treatment. These models will be used across members of the Atropos Evidence Network and integrated directly at the point of care to improve experiences for both patients and providers. Atropos Health will use real-world data from the Atropos Evidence Network, which includes GENEVA OS®, to train these models.
Health Technology Insights: Liberty HealthShare Offers Affordable Health Coverage Option
Rodney Gillespie, Head of Oncology at Novartis US, added, “At Novartis, we are committed to making a meaningful difference for patients. Using AI and machine learning to speed up diagnosis and treatment has the potential to greatly improve patient outcomes by getting them the right care faster. Our collaboration with Atropos Health to develop an AI model for PNH reflects this commitment, as it moves forward with precision health, possibly enabling earlier diagnosis and timely care, which can reduce delays that greatly impact patients’ lives.”
Paroxysmal nocturnal hemoglobinuria is a rare and chronic blood disorder caused by a mutation in some bone marrow stem cells. This mutation causes red blood cells to be destroyed early by the body’s complement system. About 10 to 20 people per million worldwide live with PNH. While it can develop at any age, it is often diagnosed in people aged 30 to 40.
This announcement comes after earlier releases from Atropos Health about their AI model training capabilities. Members of the Atropos Evidence Network can use the network to provide AI-driven insights to clinicians. Atropos Health is also working with Arcadia to help healthcare organizations deliver advanced precision medicine at scale. This partnership supports faster clinical decision-making with AI-driven insights that combine real-world evidence and patient records to improve health outcomes while reducing costs. Other healthcare organizations are also working with Atropos Health on AI for precision medicine and developing specialized models within the Atropos Evidence Network.
Health Technology Insights: The Braff Group Advises IV Solutions, LLC in its Sale to Singlepoint Healthcare
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
